Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
NCT00082108
Congenital Myotonic Dystrophy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Rochester, New York, United States
View Trial DetailsNCT Number: NCT05224778
The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and develop biomarkers for the condition.
Interested in participating?
Request InfoUp to 59 month
All sexes
Observational
Centro Clinico NeMO, Milan, Italy
Myotonic dystrophy type-1 (DM1) is an autosomal dominant disorder caused by a toxic CTG repeat expansion in the 3'UTR of the DMPK gene. DM1 is the most common adult-onset muscular dystrophy, with an overall prevalence of 1:8000. In approximately 10-20% of individuals with DM1, the onset of symptoms occurs at birth, which is known as congenital myotonic dystrophy (CDM).
Previous studies have enrolled a very limited number of children with CDM.
The rationale for this study is to include a larger population of patients with CDM in order to determine developmental milestones, measures of physical and cognitive function and quality of life, and correlate functional outcome measures with potential biomarkers in CDM .
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Through study completion at 18 months
Milestone Assessment using Peabody definitions: This survey would ask parents to assess the age of motor milestones in days, months of infant age. Birth history, including prematurity, ventilatory status, and feeding problems would also be collected on the CRF. Feeding and ventilatory support, as well as height and weight will be collected at each study visit.
Time frame: Through study completion at 18 months
A blinded, standardized video assessment tabulating language milestones by a trained rater will be conducted at each visit.
Time frame: Through study completion at 18 months
The Vineland will be administered by an interviewer to ensure standardized intake of data. This assessment will capture the adaptive function, including gross motor and fine motor, as reported by the parent proxy.
Time frame: Through study completion at 18 months
The congenital and childhood myotonic dystrophy health index is a disease specific patient or proxy reported outcome measure specific to these conditions. The current study will utilize the proxy version.
Time frame: Through study completion at 18 months
This assessment asks parents for global impression of change related to the baseline visit and will be used as an anchoring measure for the statistical analyses.
Time frame: Through study completion 18 months
The GMFM assesses functional abilities like lying/rolling, sitting, crawling/kneeling, standing, and walking, running, and jumping.
Time frame: Baseline
Fine needle muscle biopsy:On the baseline visit, a fine needle aspirate will be performed. Biopsy will only be peformed once to minimize the risk. The procedure will be performed with local anesthesia (1% lidocaine without epinephrine and free of preservatives) of the vastus lateralis. Following lidocaine injection, a fine needle will be used to aspirate the quadriceps muscle to obtain a total of one aspirate. The aspirate will be flash frozen in liquid nitrogen. A similar procedure has been performed on adults with DM1, and the average biopsy yields sufficient tissue for RNA-Seq analysis.
Time frame: Baseline, month 12, month 18
DNA and RNA samples will be processed by Virginia Commonwealth University.
Time frame: Baseline, month 12, month 18
Lean muscle mass will be evaluated using serial DEXA scans as an exploratory endpoint. All sites will use a Hologic DEXA scanner. Investigators will evaluate whole body lean mass, left and right arm lean mass, and left and right leg lean mass. Particularly early in childhood, investigators would expect rapid changes in lean muscle mass. If there were a divergence between controls and subjects with CDM, this would provide evidence that CDM is a disorder of muscle maturity, as well as provide a potential biomarker.
Time frame: Through study completion at 18 months
The WHO Motor Milestones is a set of 6 standardized motor milestones that include 1) Sitting without support, 2) Standing with assistance, 3) Hands-&-knees crawling, 4) Walking with assistance, 5) Standing alone, and 6) Walking alone.
Contact information is provided by the study sponsor or research team.
Jennifer Raymond
CONTACT
Ruby Langeslay
CONTACT
Virginia Commonwealth University
Other
Assessing Pediatric Endpoints in DM1 (ASPIRE-DM1)
Acronym: ASPIRE-DM1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00082108
Congenital Myotonic Dystrophy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Rochester, New York, United States
View Trial DetailsNCT06747884
Childhood Myotonic Dystrophy, Congenital Myotonic Dystrophy
Richmond, Virginia, United States
View Trial DetailsNCT05004129
Congenital Myotonic Dystrophy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Little Rock, Arkansas, United States
View Trial DetailsNCT02398786
Congenital Myotonic Dystrophy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Oakland, California, United States
View Trial Details